Dynavax Technologies Corporation (DVAX)
- Previous Close
10.87 - Open
10.89 - Bid 10.74 x 100
- Ask 10.80 x 100
- Day's Range
10.67 - 11.00 - 52 Week Range
9.74 - 15.15 - Volume
992,167 - Avg. Volume
2,117,063 - Market Cap (intraday)
1.411B - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
82.85 - EPS (TTM)
0.13 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.50
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
www.dynavax.com408
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DVAX
View MorePerformance Overview: DVAX
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVAX
View MoreValuation Measures
Market Cap
1.41B
Enterprise Value
926.48M
Trailing P/E
82.85
Forward P/E
53.76
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.67
Price/Book (mrq)
2.20
Enterprise Value/Revenue
3.71
Enterprise Value/EBITDA
28.02
Financial Highlights
Profitability and Income Statement
Profit Margin
6.88%
Return on Assets (ttm)
-0.79%
Return on Equity (ttm)
2.82%
Revenue (ttm)
249.69M
Net Income Avi to Common (ttm)
17.18M
Diluted EPS (ttm)
0.13
Balance Sheet and Cash Flow
Total Cash (mrq)
735.61M
Total Debt/Equity (mrq)
39.71%
Levered Free Cash Flow (ttm)
24.81M